The main purpose of this legislation is to change the tax code so that companies cannot deduct expenses related to advertising and promoting certain drugs directly to consumers. This is intended to reduce the financial incentives for pharmaceutical companies to spend heavily on advertising, which could lead to lower drug prices and more responsible marketing practices.